Stemsynergy Therapeutics Inc.

Stemsynergy Therapeutics Inc., a for-profit biopharmaceutical company headquartered in Miami, Florida, operates as a federal grant recipient developing novel small-molecule oncology therapeutics through National Institutes of Health funding. The company functions exclusively as a prime recipient on federal grants; the source shows no contract work or subcontracting relationships.

Stemsynergy's capability portfolio centers on preclinical and early development of targeted cancer drugs, specifically small-molecule inhibitors designed to disrupt oncogenic signaling pathways. Recent work includes a $399,998 Phase I SBIR award from the National Cancer Institute (CFDA 93.395, Cancer Treatment Research program) awarded September 3, 2026, to develop WNT pathway inhibitors for colorectal cancer treatment, focusing on optimization of the lead compound SSTB-178 and its analogues that disrupt v-catenin and BCL-9 binding to suppress WNT signaling in cancer cells, with performance through August 31, 2027. Earlier Phase I and Phase II SBIR grants from NCI (April 5, 2022) supported development of small-molecule MYC degraders targeting C-MYC and N-MYC-dependent cancers, with lead compounds SSTA-315 and SSTA-152 advancing through preclinical efficacy and IND-enabling toxicity studies. A Phase I award from April 5, 2022 (completed March 31, 2023) targeted N-MYC degraders for neuroblastoma and other neuroendocrine cancers.

The company's customer base is entirely within the Department of Health and Human Services, concentrated at the National Cancer Institute (10 of 15 total awards), with three additional awards distributed across HHS proper and the National Institute of General Medical Sciences. Across fifteen awards spanning 2009 to September 2026, Stemsynergy has obligated $19.9 million in combined federal grant value. Only one award completes in the next twenty-four months, presenting minimal immediate recompete exposure. The vendor's federal footprint is exclusively grant-funded basic and preclinical drug development, with no procurement or contract vehicles involved.